The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Cancer of the Ovary
Abstract
Patients with ovarian cancer usually present with advanced disease, and the disease is generally managed with surgical resection followed by platinum-based chemotherapy. Recent chemotherapeutic advances have led to improved survival, and a better understanding of genetic risk factors has permitted a tailored approach to preventive strategies, such as bilateral salpingo-oophorectomy in selected women. This review describes the clinical features of ovarian cancer and recent advances in postoperative management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Boring, C. C., Squires, T. S., & Tong, T. (1993) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.43.1.7 · Cited by 966
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck, A., Kamel, A., Whitaker, R. S., Kerns, B. J., Olt, G. J., Kinney, R., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Marks, P. J. (1990) · PubMed · Cited by 860
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., et al. (1996) · Nature Genetics · doi:10.1038/ng0396-333 · Cited by 839
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.-Y., Colombat, P., Goldstone, A. H., Gorin, N. C., Flesh, M., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706113162401 · Cited by 771
Gianni, A., Bregni, M., Stern, A., Siena, S., Tarella, C., Pileri, A., & Bonadonna, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90711-3 · Cited by 740
Ovarian Tumors in a Cohort of Infertile Women
Rossing, M. A., Daling, J. R., Weiss, N. S., Moore, D. E., & Self, S. G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409223311204 · Cited by 721
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Granulosa Cell Tumor of the Ovary
Schumer, S. T., & Cannistra, S. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.019 · Cited by 674
Self-citationOral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod, S. A., Risch, H., Moslehi, R., Dørum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390702 · Cited by 615
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Familial breast-ovarian cancer locus on chromosome 17q12-q23
LENOIR, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)90076-2 · Cited by 517
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
(ICON1), I. C. O. N. 1., & European Organisation for Research and Treatment of Cancer Collaborators–Adjuvant ChemoTherapy In Ovarian Neoplasm (EORTC–ACTION) (2003) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.105 · Cited by 443
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437
Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1
Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351901 · Cited by 423
Infertility, Fertility Drugs, and Ovarian Cancer: A Pooled Analysis of Case-Control Studies
Ness, R. B. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.3.217 · Cited by 422
Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450401 · Cited by 385
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Clinical Features of Hypersensitivity Reactions to Carboplatin
Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., & Belinson, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1141 · Cited by 365
Louie, K. G., Behrens, B. C., Kinsella, T. J., Hamilton, T. C., Grotzinger, K. R., McKoy, W. M., Winker, M. A., & Ozols, R. F. (1985) · PubMed · Cited by 333
Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study
Hankinson, S. E. (1993) · JAMA · doi:10.1001/jama.270.23.2813 · Cited by 330
Breast and ovarian cancer incidence after infertility and in vitro fertilisation
Venn, A., Watson, L., Lumley, J. M., Gilles, G., King, C., & Healy, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91687-3 · Cited by 329
Bookman, M. A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., & Fields, S. Z. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3345 · Cited by 321
Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & Mortel, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.457 · Cited by 321
Piver, M. S., Jishi, M. F., Tsukada, Y., & Nava, G. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2751::aid-cncr2820710911>3.0.co;2-j · Cited by 321
Alberts, D. S., Green, S., Hannigan, E. V., O’Toole, R. V., Stock-Novack, D., Anderson, P., Surwit, E. A., Malvlya, V. K., Nahhas, W. A., & Jolles, C. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.706 · Cited by 317
Assessing the Risk of Breast Cancer
Armstrong, K., Eisen, A., & Weber, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420807 · Cited by 317
BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302853 · Cited by 314
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
Tonin, P., Weber, B., Offit, K., Couch, F., Rebbeck, T. R., Neuhausen, S., Godwin, A. K., Daly, M., Wagner-Costalos, J., Berman, D., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1179 · Cited by 313
The Hereditary Nonpolyposis Colorectal Cancer Syndrome: Genetics and Clinical Implications
Chung, D. C., & Rustgi, A. K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00012 · Cited by 306
Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E., van Oosterom, A. T., Willemse, P. H., Heintz, A. P., van Lent, M., Trimbos, J. B., Bouma, J., & Vermorken, J. B. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1157 · Cited by 305
Granberg, S., Wikland, M., & Jansson, I. (1989) · Gynecologic Oncology · doi:10.1016/0090-8258(89)90031-0 · Cited by 301
Furneaux, H. M., Rosenblum, M. K., Dalmau, J., Wong, E., Woodruff, P., Graus, F., & Posner, J. B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222604 · Cited by 287
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer
Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K., & Stettner, H. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90099-q · Cited by 285
Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986) · Cancer · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j · Cited by 278
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1174 · Cited by 276
Lysophosphatidic acid is a bioactive mediator in ovarian cancer
Fang, X. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00179-8 · Cited by 264
ELIAS, A. D., Ayash, L. J., Anderson, K. C., et al. (1992) · Blood · doi:10.1182/blood.v79.11.3036.3036 · Cited by 257
Skates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER
Jacobs, I., Bridges, J., Reynolds, C., Stabile, I., Kemsley, P., Grudzinskas, J., & Oram, D. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90351-0 · Cited by 241
Malkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., Mortel, R., Berek, J. S., Bast, R. C., & Ritts, R. E. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80081-4 · Cited by 227
Howell, S. B., Zimm, S., Markman, M., Abramson, I. S., Cleary, S., Lucas, W. E., & Weiss, R. J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1607 · Cited by 221
Location of BRCA1 in Human Breast and Ovarian Cancer Cells
Scully, R., Ganesan, S., Brown, M., De Caprio, J. A., Cannistra, S. A., Feunteun, J., Schnitt, S., & Livingston, D. M. (1996) · Science · doi:10.1126/science.272.5258.123 · Cited by 217
Self-citationBAX enhances paclitaxel-induced apoptosis through a p53-independent pathway
Strobel, T., Swanson, L., Korsmeyer, S., & Cannistra, S. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14094 · Cited by 216
Self-citationFAMILIAL OVARIAN CANCER: A POPULATION-BASED CASE-CONTROL STUDY1
SCHILDKRAUT, J. M., & THOMPSON, W. D. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114994 · Cited by 215
Clinical Proteomics: Personalized Molecular Medicine
Liotta, L. A., Kohn, E. C., & Petricoin, E. F. (2001) · JAMA · doi:10.1001/jama.286.18.2211 · Cited by 213
Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations
Levine, D. A., Argenta, P. A., Yee, C. J., Marshall, D. S., Olvera, N., Bogomolniy, F., Rahaman, J. A., Robson, M. E., Offit, K., Barakat, R. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.131 · Cited by 206
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
David, Y. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 200
Chemoprevention of Breast Cancer: A Model for Change
Jordan, V. C., & Morrow, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.1 · Cited by 197
Markman, M., Reichman, B., Hakes, T., Jones, W., Lewis, J. L., Rubin, S., Almadrones, L., & Hoskins, W. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1801 · Cited by 191
Paley, P. J., Swisher, E. M., Garcia, R. L., Agoff, S. N., Greer, B. E., Peters, K. L., & Goff, B. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6071 · Cited by 189
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C., Schnipper, L., Frei, E., & Henner, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.651 · Cited by 188
Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., & Reed, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1165 · Cited by 179
Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
Lai, G.-M., Ozols, R. F., Young, R. C., & Hamilton, T. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.535 · Cited by 167
Negri, E., Franceschi, S., Tzonou, A., Booth, M., La Vecchia, C., Parazzini, F., Beral, V., Boyle, P., & Trichopoulos, D. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490110 · Cited by 167
Hakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., Chapman, D., Almadrones, L., & Lewis, J. L. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90305-3 · Cited by 162
Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells
Alper, Ö., Bergmann‐Leitner, E. S., Bennett, T. A., Hacker, N. F., Stromberg, K., & Stetler‐Stevenson, W. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1375 · Cited by 158
Seltzer, V., Drukker, B. H., Gillespie, B. W., Gossfeld, L. M., Grigsby, P. W., Harvey, H. A., Hendricks, C. B., Hummel, S., Makuch, R. W., Monaco, G. P., et al. (1995) · JAMA · doi:10.1001/jama.273.6.491 · Cited by 154
Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report
Markman, M., Iseminger, K. A., Hatch, K. D., Creasman, W. T., Barnes, W. A., & DuBeshter, B. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0181 · Cited by 151
Ultrasound screening for familial ovarian cancer
Bourne, T., Whitehead, M. I., Campbell, S. C., Royston, P. J., Bhan, V., & Collins, W. P. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90051-6 · Cited by 121
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer
Rodriguez, G. C., Berchuck, A., Whitaker, R. S., et al. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90508-o · Cited by 114
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
Niloff, J. M., KNAPP, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., Mortel, R., Whitney, C., Zurawski, V. R., & Bast, R. C. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90077-3 · Cited by 113
Young, R. C., Brady, M. F., Nieberg, R. K., Long, H. J., Mayer, A. R., Lentz, S. S., Hurteau, J. A., & Alberts, D. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.154 · Cited by 106
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman, B. S., Markman, M. M., Hakes, T. B., Hoskins, W. J., Rubin, S. C., Jones, W., Almadrones, L., Ochoa, M., Chapman, D. S., & Saigo, P. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1327 · Cited by 89
Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection
Whittemore, A. S. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1334 · Cited by 81
Hexamethylmelamine as a single second-line agent in ovarian cancer
Manetta, A., MacNeill, C., Lyter, J. A., Scheffler, B., Podczaski, E. S., Larson, J. E., & Schein, P. S. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90115-2 · Cited by 74
Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer
Burger, R. A., DiSaia, P. J., Roberts, J. A., O’Rourke, M. A., Gershenson, D. M., Homesley, H. D., Lichtman, S. M., Barnes, W. A., Moore, D. H., & Monk, B. J. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5243 · Cited by 69
Epithelial ovarian cancer in the elderly: The memorial sloan-kettering cancer center experience
Markman, M. M., Lewis, J. L., Saigo, P. E., Hakes, T., Jones, W. B., Rubin, S. C., Reichman, B. S., Barakat, R. R., Curtin, J. P., Almadrones, L., et al. (2010) · Cancer · doi:10.1002/cncr.2820710222 · Cited by 67
The Ethics of Early Stopping Rules: Who Is Protecting Whom?
Cannistra, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.150 · Cited by 65
Self-citationPiver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Emrich, L. J., & Hartman, A. B. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.11.1679 · Cited by 64
Cannistra, S. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1158 · Cited by 61
Self-citationShpall, E. J., Clarke-Pearson, D., Soper, J. T., Berchuck, A., Jones, R. B., Bast, R. C., Ross, M., Lidor, Y. J., Vanacek, K., Tyler, T., et al. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90079-z · Cited by 50
Early-Stage Ovarian Cancer: To Treat or Not To Treat
Young, R. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.94 · Cited by 42
Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price?
Garber, J. E., & Hartman, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.926 · Cited by 20
Why should the clonogenic cell assay be prognostically important in ovarian cancer?
Cannistra, S. A. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.368 · Cited by 5
Self-citation
Cited by
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
MicroRNA Signatures in Human Ovarian Cancer
Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.-G., Alder, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1936 · Cited by 1,394
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Metadata
- Authors
- Cannistra, S. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-09
- Volume
- 351
- Issue
- 24
- Pages
- 2519-2529
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1998258610
- Cited by
- 2,129
- References
- 100
- FWCI
- 73.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.